SCHEMBL14697214

SCHEMBL14697214

COc1cc(-c2oc3c(ccc4ccccc43)c(=O)c2O)ccc1O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 12/20 0.85
ABCB1 P08183 4/20 0.85
CSNK2A2 P19784 2/20 0.67
CSNK2B P67870 2/20 0.67
CSNK2A1 P68400 2/20 0.67
ABCC1 P33527 5/20 0.65
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
LMNA P02545 2/20 0.61
TP53 P04637 2/20 0.61
CYP3A4 P08684 2/20 0.61
MAPT P10636 2/20 0.61
HPGD P15428 2/20 0.61
CASP1 P29466 2/20 0.61
CASP7 P55210 2/20 0.61
HSD17B10 Q99714 2/20 0.61
ALOX15 P16050 1/20 0.61
MAPK1 P28482 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697044 0.90 ABCG2 (0.69) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL14697063 0.86 ABCG2 (0.73) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL14708630 0.84 ABCG2 (0.79) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL14697207 0.84 ABCG2 (0.79) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL14697050 0.84 ABCG2 (0.73) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL14697069 0.82 ABCG2 (0.74) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL15844041 0.82 KDM4E (0.83) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL14708633 0.81 CSNK2A2 (1.00) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL17292888 0.79 ABCG2 (1.00) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1
SCHEMBL15630201 0.79 ABCG2 (0.69) ABCG2ABCB1CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2014-07-03 US claimed
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-07-03 US claimed
EP-2741609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS Salk Institute for Biological Studies (US) 2014-06-18 EP claimed
WO-2013025484-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA LAPCHAK PAUL A (US) 2013-02-21 WO claimed
WO-2013025498-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SCHUBERT DAVID R (US) 2013-02-21 WO claimed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2014-07-03 US disclosed
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-07-03 US disclosed
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-07-03 US disclosed
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2014-07-03 US disclosed
EP-2741609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS Salk Institute for Biological Studies (US) 2014-06-18 EP disclosed
WO-2013025484-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA LAPCHAK PAUL A (US) 2013-02-21 WO disclosed
WO-2013025484-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA LAPCHAK PAUL A (US) 2013-02-21 WO disclosed
WO-2013025498-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SCHUBERT DAVID R (US) 2013-02-21 WO disclosed
WO-2013025498-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SCHUBERT DAVID R (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA GPX1, KEAP1, GPX4 ABCG2 4578/4885ABCB1 4736/4885CSNK2A2 4845/4885
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS GSR, IAPP, GCLC ABCG2 1504/4885ABCB1 2707/4885CSNK2A2 4874/4885
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS GSR, IAPP, GCLC ABCG2 1504/4885ABCB1 2707/4885CSNK2A2 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.